CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Medicine, Inc. (NASDAQ:FMI) today announced the appointment of life
sciences executive Lisa Ricciardi to the newly created position of
senior vice president, corporate and business development. In this role,
Ms. Ricciardi will be responsible for overseeing the company's
biopharmaceutical partnerships as well as corporate and business
development activities across the company.
"Lisa brings a tremendous level of experience and expertise in areas
that will help Foundation Medicine further its vision to transform
cancer care," commented Steven J. Kafka, Ph.D., chief operating officer
of Foundation Medicine. "Her leadership will help us to accelerate the
advancement of our new product pipelines for both clinical and
technology products, and to explore new collaborative opportunities that
we expect will increase our impact for patients and other key
stakeholders, while also driving shareholder value."
Prior to joining Foundation Medicine, Ms. Ricciardi held numerous senior
business development and marketing roles in pharmaceuticals, healthcare
services, and finance. Ms. Ricciardi spent several years at Pfizer
culminating in the role of senior vice president, licensing and
development, where she led more than two dozen complex, multinational,
multi-year deals across a host of disease areas, including oncology. Ms.
Ricciardi was also a venture partner for Essex Woodlands Health
Ventures, and served as senior vice president of U.S. and international
business development in the healthcare services sector at Medco Health
Solutions. Most recently, Ms. Ricciardi served as a consultant to the
specialty pharmacy division of DaVita, a full-service pharmacy
specializing in renal care.
Ms. Ricciardi is currently a member of the Board of Directors of United
Drug Group, PLC in Dublin, Ireland, and a director with Chimerix in
Durham, North Carolina. Ms. Ricciardi earned an MBA from the University
of Chicago and a bachelor's degree with honors from Wesleyan University
in Middletown, Connecticut.
About Foundation Medicine
Foundation Medicine (NASDAQ: FMI) is a molecular information company
dedicated to a transformation in cancer care in which treatment is
informed by a deep understanding of the genomic changes that contribute
to each patient's unique cancer. The company's clinical assays,
FoundationOne for solid tumors and FoundationOne Heme for hematologic
malignancies, sarcomas and pediatric cancers, provide a fully
informative genomic profile to identify the molecular alterations in a
patient's cancer and match them with relevant targeted therapies and
clinical trials. Foundation Medicine's molecular information platform
aims to improve day-to-day care for patients by serving the needs of
clinicians, academic researchers and drug developers to help advance the
science of molecular medicine in cancer. For more information, please
or follow Foundation Medicine on Twitter (@FoundationATCG).
Foundation Medicine® and FoundationOne®
are registered trademarks of Foundation Medicine, Inc.
Pure Communications, Inc.
Khaled Habayeb, 617-418-2283
Source: Foundation Medicine, Inc.
News Provided by Acquire Media